Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.

Machine translation Machine translation
类别 Primary study
期刊Neurology
Year 1992

此文章收錄於 4 Systematic reviews Systematic reviews (4 references)

This article is part of the following publication threads:
Loading references information
以确定影响静脉重组组织型纤溶酶原激活剂(RT-PA),血管和神经系统的成果,我们招收从症状发作31例急性颈内动脉缺血性中风的领土在一项随机,双盲,安慰剂控制在6小时内研究。我们给RT-PA“(20年或30万国际单位的剂量duteplase [缪])或安慰剂静脉注射60分钟的患者随机分配到三组。之间基线和postinfusion的血管造影的对比表明,全部或部分再灌注治疗的患者50%(5/10)发生30 MIU的RT-PA,20 MIU的RT-PA治疗的44%(4/9),在对照组和17%(2/12)。在大脑中动脉闭塞的患者,发生在再灌注30 MIU的组71%(5/7),在20 MIU的组67%(4/6),并在13%(1/8)对照组。30 MIU的RT-PA治疗的患者表现出显着的早期和较好的临床改善,神经规模计算,比安慰剂组。1各组患者发生脑实质出血和出血性脑梗塞临床微不足道的频率为治疗组之间的比较。没有重大的系统性并发症发生在任何一组。这些结果支持了生产快速溶栓和神经功能恢复中风发病后不久,RT-PA静脉滴注的疗效,它可能是在大脑中动脉血栓闭塞患者具有特殊价值。
Epistemonikos ID: 884f8c3b6ef264cf58f2e6c8e7e288cd4421f063
First added on: May 06, 2012
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use